Equities

Harbin Pharmaceutical Group Co Ltd

600664:SHH

Harbin Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)3.03
  • Today's Change-0.01 / -0.33%
  • Shares traded18.19m
  • 1 Year change-10.62%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,9562,0641,191
Total Receivables, Net5,1855,0514,908
Total Inventory1,9241,8042,064
Prepaid expenses223268168
Other current assets, total107372402
Total current assets10,3969,5608,733
Property, plant & equipment, net2,4722,6412,835
Goodwill, net393939
Intangibles, net478492531
Long term investments1038582
Note receivable - long term------
Other long term assets0.970.970.97
Total assets14,11213,43612,842
LIABILITIES
Accounts payable2,2812,3382,176
Accrued expenses634699644
Notes payable/short-term debt4,5424,1724,371
Current portion long-term debt/capital leases135140140
Other current liabilities, total651653524
Total current liabilities8,2438,0027,855
Total long term debt647796
Total debt4,7414,3894,607
Deferred income tax6.912.991.68
Minority interest699620573
Other liabilities, total376403470
Total liabilities9,3889,1058,995
SHAREHOLDERS EQUITY
Common stock2,5212,5262,518
Additional paid-in capital685689675
Retained earnings (accumulated deficit)3,2822,8902,426
Treasury stock - common(3.98)(13)(16)
Unrealized gain (loss)(1754)(1754)(1753)
Other equity, total(6.44)(5.79)(3.52)
Total equity4,7244,3313,847
Total liabilities & shareholders' equity14,11213,43612,842
Total common shares outstanding2,5192,5172,507
Treasury shares - common primary issue2.779.0711
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.